New treatments for rheumatoid arthritis: Available and upcoming slow- acting antirheumatic drugs

Postgraduate Medicine

Volumn 106, Issue 4, 1999, Pages 82-92

  Fye, Kenneth H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CONFERENCE PAPER; DRUG MECHANISM; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; RASH; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032820847     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1999.10.1.703     Document Type: Conference Paper

References (27)

1. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984;11(2):158-61
2. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41(9):1591-602
3. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13(5):841-5
4. Harris ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322(18):1277-89
5. Fries JF. Safety issues related to DMARD therapy. J Rheumatol (Suppl) 1990;25:14-7
6. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334(20):1287-91
7. Van Rijthoven AW, Dijkmans BA, Goei The HS, et al. Cyclosporine treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis 1986;45(9):726-31
8. Williams RO, Mauri C, Mason LJ, et al. Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combined therapy. Arthritis Rheum 1998;41(10):1806-12
9. Van Rijthoven AW, Dijkmans BA, The HS, et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. J Rheumatol 1991;18(6): 815-20
10. Landewe RB, Goei The HS, van Rijthoven AW, et al. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37(5):637-43
11. Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998;25(12):2331-8
12. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol (Suppl) 1998;53:20-6
13. Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726: inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996;52(4):527-34
14. Furst D, Cannon GW, Fox R. Onset of effect and duration of response to leflunomide treatment of active rheumatoid arthritis (RA) compared to placebo or methotrexate. (Abstr) Arthritis Rheum 1998;41(Suppl):155S
15. Rozman B. Clinical experience with leflunomide in rheumatoid arthritis: Leflunomide Investigators' Group. J Rheumatol (Suppl) 1998;53:27-32
16. Tugwell P, Bombardier C, Strand V, et al. Treatment of active rheumatoid arthritis with leflunomide improves functional activities and health related quality of life (HRQOL): Leflunomide Investigators Group. (Abstr) Arthritis Rheum 1998;41(Suppl):154S
17. Schiff M, Kaine J, for the Leflunomide Investigators Group. X-ray analysis of 12 months treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. (Abstr) Arthritis Rheum 1998;41(Suppl):155S
18. Deleuran BW, Chu CQ, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992; 35(10):1170-8
19. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38(2):151-60
20. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36(12):1681-90
21. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9):1552-63
22. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344(8930):1125-7
23. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35(10): 1160-9
24. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3): 141-7
25. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor recepton:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9
26. Firestein GS, Boyle DL, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37(5):644-52
27. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41(12):2196-204